Salutaris Medical Devices, Inc. (SalutarisMD®), is a clinical-stage company anticipating first sales revenue in early 2017. SalutarisMD is developing a minimally invasive treatment for Wet Age-related Macular Degeneration (Wet AMD). Results of a small Phase I/II human study produced very encouraging patient outcomes, including case reports of durable response (or colloquially stated: “patients cured of their blindness”); specifically patient outcomes with return of vision, requiring no additional interventions for two years, and absence of the pathologic lesion.
Such durable outcomes are generally not achieved by the current therapies (e.g., Lucentis®), and thus SalutarisMD has achieved a profound milestone.
Laurence Marsteller, MD
Laurence Marsteller MS, MD has 30 years of experience in business, healthcare and medical device development. He began his career as an Investment Banking analyst.